Cargando…

Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report

Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a rare disorder caused by somatic mosaicism for the gain of function RAS mutations . Affected patients have segmental epidermal nevi, dysplastic cortical bony lesions, and fibroblast growth factor-23 (FGF23)–mediated hypophosphatemic rickets. He...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khadora, Manal, Mughal, M. Zulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502709/ https://www.ncbi.nlm.nih.gov/pubmed/34660853 http://dx.doi.org/10.1016/j.bonr.2021.101138

Ejemplares similares

A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome
por: Merz, Lea Maria, et al.
Publicado: (2022)

Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
por: Mughal, M. Zulf, et al.
Publicado: (2023)

Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review
por: Jurca, Claudia Maria, et al.
Publicado: (2022)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022)

SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019)

Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
por: Martín Ramos, Silvia, et al.
Publicado: (2020)

Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
por: Murari, Keerti, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia
por: Lee, Sun Ku, et al.
Publicado: (2021)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone
por: Ertl, Diana-Alexandra, et al.
Publicado: (2022)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

Successful treatment with MEK‐inhibitor in a patient with NRAS ‐related cutaneous skeletal hypophosphatemia syndrome
por: Carli, Diana, et al.
Publicado: (2022)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
por: Brener, Avivit, et al.
Publicado: (2021)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
por: Brener, Rafi, et al.
Publicado: (2022)

Dramatic Transformation After Burosumab in a Young Boy With X-linked Hypophosphatemia: A Life-Changing Saga
por: Baradhi, Krishna
Publicado: (2022)

SUN-525 Burosumab Experience In A UK Adolescent Population
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial
por: Namba, Noriyuki, et al.
Publicado: (2022)

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
por: Imel, Erik A, et al.
Publicado: (2023)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
por: Takashi, Yuichi, et al.
Publicado: (2022)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review
por: Lafage-Proust, Marie-Hélène
Publicado: (2022)

FGF23 and its role in X-linked hypophosphatemia-related morbidity
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2019)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries
por: Al Juraibah, Fahad, et al.
Publicado: (2021)

Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)

OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome
por: Jan De Beur, Suzanne, et al.
Publicado: (2019)

OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
por: Carpenter, Thomas O, et al.
Publicado: (2020)

Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
por: Ovejero, Diana, et al.
Publicado: (2023)

OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program
por: Carpenter, Thomas, et al.
Publicado: (2022)

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
por: Padidela, Raja, et al.
Publicado: (2021)

SUN-524 Burosumab Initiation In A UK XLH Cohort: Real-World Use Resonates With Research Evidence
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia
por: Cheong, Hae Il, et al.
Publicado: (2018)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
por: Brandi, Maria Luisa, et al.
Publicado: (2022)

Hypophosphatemia as Unusual Cause of ARDS in Cushing’s Syndrome Secondary to Ectopic CRH Production. A Case Report
por: Mondello, Stefania, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_4os1bl3g97sq50rvnik04g93ei